JPMorgan initiates BlossomHill Therapeutics stock with overweight

JPMorgan has started coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with an Overweight rating and a price target of $28.00. BlossomHill is a clinical-stage oncology company focused on developing therapeutics with unique structural attributes. Their lead product, BH-30643, is a macrocyclic EGFR inhibitor. The company has a market capitalization of $561 million and a current stock price of $18.30, resulting in a 14% return over the past six months.

Despite being deemed overvalued according to InvestingPro analysis, BlossomHill has a strong balance sheet with more cash than debt and a robust current ratio of 7.4. JPMorgan analyst Brian Cheng projects a December 2027 price target of $28. The firm highlights the rising prevalence of resistance mutations, such as C797S, in EGFRm NSCLC, suggesting potential for BH-30643 to expand into other adjacent EGFRm segments.

BlossomHill is also developing a clinical-stage CLK inhibitor for liquid tumors and a preclinical pan-KRAS program. Recently, the company completed its initial public offering, raising $150 million, which provides additional capital for future developments.